Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346956 | 1.00 | ACE (0.47) | ACECASP1CASP8SMN1; SMN2L3MBTL1 | |
| SCHEMBL11192926 | 0.84 | ITGB1 (0.38) | ACESMN1; SMN2L3MBTL1POLBKMT2A | |
| SCHEMBL10832641 | 0.82 | MMP1 (0.38) | ACECASP1CASP8SMN1; SMN2L3MBTL1 | |
| SCHEMBL385403 | 0.81 | ACE (0.59) | ACESMN1; SMN2L3MBTL1POLBCYP2D6 | |
| SCHEMBL385463 | 0.81 | ACE (0.59) | ACESMN1; SMN2L3MBTL1POLBCYP2D6 | |
| SCHEMBL6141057 | 0.81 | ACE (0.59) | ACESMN1; SMN2L3MBTL1POLBCYP2D6 | |
| SCHEMBL5903651 | 0.80 | GSK3B (0.38) | POLBLMNA | |
| SCHEMBL385803 | 0.75 | ACE (0.61) | ACE | |
| SCHEMBL386126 | 0.75 | ACE (0.61) | ACE | |
| SCHEMBL386486 | 0.75 | ACE (0.61) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9061069-B2 | Use of constrained peptide mimic oligomers as vectorization agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-06-23 | — | — | US | disclosed |
| US-9061069-B2 | Use of constrained peptide mimic oligomers as vectorization agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-06-23 | — | — | US | disclosed |
| US-20120184480-A1 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS | UNIVERSITE DE MONTPELLIER I (FR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184480-A1 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS | UNIVERSITE DE MONTPELLIER I (FR) | 2012-07-19 | — | — | US | disclosed |
| US-20120076863-A1 | NANOPARTICULATE STABILIZED ANTI-HYPERTENSIVE COMPOSITIONS | ELAN PHARMA INTERNATIONAL LTD. | 2012-03-29 | — | — | US | disclosed |
| US-20100028439-A1 | Nanoparticulate stabilized anti-hypertensive compositions | ELAN PHARMA INTERNATIONAL LIMITED | 2010-02-04 | — | — | US | disclosed |
| US-5859239-A | Mercaptoalkanoylamino and acylmercaptoalkanoylamino benzoxazepines and benzothiazepines | E. R. SQUIBB & SONS, INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5856476-A | Processes for preparing azepiones useful as intermediates in the preparation of inhibitors of angiotensin converting enzyme and neutral endopeptidase | E. R. SQUIBBS & SONS, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5856477-A | HYPOTENSIVE AGENTS; CONGESTIVE HEART FAILURE | E. R. SQUIBB & SONS, INC. (US) | 1999-01-05 | — | — | US | disclosed |
| US-5723457-A | COMPOUMDS FOR CARDIOVASCULAR DISORDERS AND INHIBITORS OF ANGIOTENSIN CONVERTING ENZYMES | E. R. SQUIBB & SONS, INC. (US) | 1998-03-03 | — | — | US | disclosed |
| US-5552397-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0599444-A1 | Dual action inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0154904-B1 | ACYLAMINO OXO OR HYDROXY SUBSTITUTED ALKYLAMINO THIAZINES AND THIAZEPINES | E.R. Squibb & Sons, Inc. (US) | 1987-10-28 | — | — | EP | disclosed |
| US-4594341-A | Hypotensive agent | MERCK & CO., INC. (US) | 1986-06-10 | — | — | US | disclosed |
| EP-0154904-A1 | Acylamino oxo or hydroxy substituted alkylamino thiazines and thiazepines | E.R. Squibb & Sons, Inc. (US) | 1985-09-18 | — | — | EP | disclosed |
| US-4512988-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-04-23 | — | — | US | disclosed |
| EP-0120728-A1 | Thiazine and thiazepine containing compounds | E.R. Squibb & Sons, Inc. (US) | 1984-10-03 | — | — | EP | disclosed |
| EP-0068173-B1 | PERHYDRO-1,4-THIAZEPIN-5-ONE AND PERHYDRO-1,4-THIAZOCIN-5-ONE DERIVATIVES, PROCESS FOR PREPARING AND PHARMCEUTICAL COMPOSITION CONTAINING THE SAME | MERCK & CO. INC. (US) | 1984-09-26 | — | — | EP | disclosed |
| US-4460579-A | HYPOTENSIVE AGENTS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1984-07-17 | — | — | US | disclosed |
| EP-0068173-A1 | Perhydro-1,4-thiazepin-5-one and perhydro-1,4-thiazocin-5-one derivatives, process for preparing and pharmceutical composition containing the same | MERCK & CO. INC. (US) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184480-A1 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS | DNPEP, IAPP, VIP | ACE 167/4885CASP1 1559/4885CASP8 1794/4885 |
| US-20100028439-A1 | Nanoparticulate stabilized anti-hypertensive compositions | AGTR1, REN, AGTR2 | ACE 24/4885CASP1 3736/4885CASP8 4391/4885 |
| US-20120076863-A1 | NANOPARTICULATE STABILIZED ANTI-HYPERTENSIVE COMPOSITIONS | AGTR1, REN, AGTR2 | ACE 24/4885CASP1 3736/4885CASP8 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.